<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="503">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03100318</url>
  </required_header>
  <id_info>
    <org_study_id>FYU-981-011</org_study_id>
    <nct_id>NCT03100318</nct_id>
  </id_info>
  <brief_title>Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout</brief_title>
  <official_title>Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuji Yakuhin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mochida Pharmaceutical Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fuji Yakuhin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout
      for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter,
      randomized, double-blind, ascending dose regimen.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent reduction from baseline in serum urate level at the final visit</measure>
    <time_frame>14 weeks</time_frame>
    <description>Percent reduction from baseline in serum urate level at the final visit</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hyperuricemia With or Without Gout</condition>
  <arm_group>
    <arm_group_label>FYU-981</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Benzbromarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FYU-981</intervention_name>
    <description>Oral daily dosing for 14 weeks</description>
    <arm_group_label>FYU-981</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzbromarone</intervention_name>
    <description>Oral daily dosing for 14 weeks</description>
    <arm_group_label>Benzbromarone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyperuricemic or gout patients

          -  Serum urate level:

        &gt;= 7.0mg/dL in patients with history of gout, or &gt;= 8.0mg/dL in patients with
        hypertension, diabetes or metabolic syndrome, or &gt;= 9.0mg/dL

        Exclusion Criteria:

          -  Gouty arthritis within two weeks before start of study treatment

          -  Secondary hyperuricemia

          -  HbA1c: &gt;= 8.4%

          -  Uric acid-overproduction type in the classification of hyperuricemia

          -  History of, clinically significant cardiac, hematologic and hepatic disease

          -  Kidney calculi or clinically significant urinary calculi

          -  Hepatic dysfuction, or AST: &gt;=100 IU/L or ALT: &gt;=100 IU/L at the pre-examination

          -  eGFR: &lt; 30mL/min/1.73m^2

          -  Systolic blood pressure: &gt;= 180 mmHg

          -  Diastolic blood pressure: &gt;= 110 mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Masahiko Fushimi</last_name>
    <phone>+81-48-644-3403</phone>
    <email>m-fushimi@fujiyakuhin.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuji Yakuhin Co., Ltd.</name>
      <address>
        <city>Saitama-shi</city>
        <state>Saitama</state>
        <zip>330-9508</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masahiko Fushimi</last_name>
      <phone>+81-48-644-3403</phone>
      <email>m-fushimi@fujiyakuhin.co.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>April 3, 2017</lastchanged_date>
  <firstreceived_date>March 29, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gout</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Benzbromarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
